JP7328761B2 - 多価多重特異性ｏｘ４０結合融合タンパク質 - Google Patents

多価多重特異性ｏｘ４０結合融合タンパク質 Download PDF

Info

Publication number
JP7328761B2
JP7328761B2 JP2018535298A JP2018535298A JP7328761B2 JP 7328761 B2 JP7328761 B2 JP 7328761B2 JP 2018535298 A JP2018535298 A JP 2018535298A JP 2018535298 A JP2018535298 A JP 2018535298A JP 7328761 B2 JP7328761 B2 JP 7328761B2
Authority
JP
Japan
Prior art keywords
vhh
fusion protein
linker
binding
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018535298A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019504062A (ja
Inventor
ブレンダン ピー． エッケルマン
ジョン シー． ティマー
チェルシー ハタ
カイル エス． ジョーンズ
アブラヒム フセイン
アミール エス． ラザイ
ブライアン ベックランド
ラジェイ パンディット
マイク カプラン
ルーカス レイソン
クイン デヴロー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aatd Inc
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of JP2019504062A publication Critical patent/JP2019504062A/ja
Priority to JP2022154355A priority Critical patent/JP2022185021A/ja
Application granted granted Critical
Publication of JP7328761B2 publication Critical patent/JP7328761B2/ja
Priority to JP2025028636A priority patent/JP2025081649A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2018535298A 2016-01-11 2017-01-11 多価多重特異性ｏｘ４０結合融合タンパク質 Active JP7328761B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022154355A JP2022185021A (ja) 2016-01-11 2022-09-28 多価多重特異性ｏｘ４０結合融合タンパク質
JP2025028636A JP2025081649A (ja) 2016-01-11 2025-02-26 多価多重特異性ｏｘ４０結合融合タンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662277027P 2016-01-11 2016-01-11
US62/277,027 2016-01-11
PCT/US2017/013070 WO2017123673A2 (en) 2016-01-11 2017-01-11 Multivalent and multispecific ox40-binding fusion proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022154355A Division JP2022185021A (ja) 2016-01-11 2022-09-28 多価多重特異性ｏｘ４０結合融合タンパク質

Publications (2)

Publication Number Publication Date
JP2019504062A JP2019504062A (ja) 2019-02-14
JP7328761B2 true JP7328761B2 (ja) 2023-08-17

Family

ID=59275443

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018535298A Active JP7328761B2 (ja) 2016-01-11 2017-01-11 多価多重特異性ｏｘ４０結合融合タンパク質
JP2022154355A Pending JP2022185021A (ja) 2016-01-11 2022-09-28 多価多重特異性ｏｘ４０結合融合タンパク質
JP2025028636A Pending JP2025081649A (ja) 2016-01-11 2025-02-26 多価多重特異性ｏｘ４０結合融合タンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022154355A Pending JP2022185021A (ja) 2016-01-11 2022-09-28 多価多重特異性ｏｘ４０結合融合タンパク質
JP2025028636A Pending JP2025081649A (ja) 2016-01-11 2025-02-26 多価多重特異性ｏｘ４０結合融合タンパク質

Country Status (13)

Country Link
US (3) US20170198051A1 (https=)
EP (1) EP3402507A4 (https=)
JP (3) JP7328761B2 (https=)
KR (1) KR20180098671A (https=)
CN (1) CN108883153A (https=)
AU (2) AU2017207318B2 (https=)
BR (1) BR112018013911A2 (https=)
CA (1) CA3009075A1 (https=)
IL (2) IL298686A (https=)
MX (2) MX2018008310A (https=)
RU (1) RU2022106508A (https=)
SG (1) SG11201805422WA (https=)
WO (1) WO2017123673A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220084444A (ko) * 2012-05-31 2022-06-21 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
KR20180098671A (ko) 2016-01-11 2018-09-04 인히브릭스, 인크. 다가 및 다중특이적 ox40-결합 융합 단백질
JP2019530640A (ja) * 2016-07-20 2019-10-24 アイジーエム バイオサイエンシズ インコーポレイテッド 多量体ｏｘ４０結合分子及びその使用
WO2018027204A1 (en) * 2016-08-05 2018-02-08 Genentech, Inc. Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
ES2981272T3 (es) 2016-09-23 2024-10-08 Merus Nv Moléculas de unión que modulan una actividad biológica expresada por una célula
US20200347143A1 (en) 2016-12-19 2020-11-05 Glenmark Pharmaceuticals S.A. Novel tnfr agonists and uses thereof
SG11201909160WA (en) 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
KR20240017409A (ko) 2017-04-13 2024-02-07 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
AU2018394939B2 (en) 2017-12-29 2022-02-24 Ap Biosciences, Inc. Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy
CN110305210B (zh) 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
KR20260046525A (ko) 2018-04-11 2026-04-07 인히브릭스 바이오사이언스, 인크. 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
EP3827019A1 (en) 2018-07-24 2021-06-02 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
WO2020036867A1 (en) * 2018-08-13 2020-02-20 Inhibrx, Inc. Ox40-binding polypeptides and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
JP7611820B2 (ja) 2018-10-11 2025-01-10 インヒブルクス バイオサイエンシズ インコーポレイテッド Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
JP2022504802A (ja) 2018-10-11 2022-01-13 インヒブルクス インコーポレイテッド ５ｔ４シングルドメイン抗体およびその治療組成物
CN120623346A (zh) 2018-10-11 2025-09-12 因荷布瑞克斯生物科学公司 Pd-1单结构域抗体及其治疗组合物
CN113166261A (zh) 2018-10-11 2021-07-23 印希比股份有限公司 B7h3单域抗体及其治疗性组合物
JP7575100B2 (ja) * 2018-11-13 2024-10-29 ジェイエヌ バイオサイエンシーズ エルエルシー 免疫細胞活性化のための二重特異性抗体
WO2020102647A1 (en) * 2018-11-15 2020-05-22 Invenra Inc. Multivalent receptor-clustering agonist antibody constructs and antigen binding proteins
WO2020144164A1 (en) * 2019-01-07 2020-07-16 Bactolife Aps Pathogen binding proteins
TWI793395B (zh) * 2019-01-25 2023-02-21 大陸商信達生物製藥（蘇州）有限公司 結合ｐｄ-ｌ１和ｏｘ４０的雙特異性抗體
JP2022553176A (ja) * 2019-10-17 2022-12-22 江蘇康寧杰瑞生物制薬有限公司 Ｏｘ４０／ｐｄ－ｌ１二重特異性抗体
WO2021084104A1 (en) * 2019-10-30 2021-05-06 Bioinvent International Ab Tetravalent antibody molecules
EP4077374A4 (en) * 2019-12-20 2023-12-27 Kisoji Biotechnology Inc. POLYPEPTIDES, PROTEIN COMPLEXES AND METHODS FOR PRODUCING THE SAME
WO2022002009A1 (zh) * 2020-06-30 2022-01-06 和铂医药(上海)有限责任公司 靶向ox40的抗体及其制备方法和应用
EP3940931A1 (de) 2020-07-14 2022-01-19 Siemens Aktiengesellschaft Verfahren zur herstellung eines rotors einer asynchronmaschine
WO2022023484A1 (en) * 2020-07-29 2022-02-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Therapeutic and diagnostic vhh antibodies against sars-cov-2 and methods for their enhancement
WO2022243341A1 (en) * 2021-05-18 2022-11-24 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding affinity for ox40
WO2023089079A1 (en) * 2021-11-19 2023-05-25 Pieris Pharmaceuticals Gmbh Novel fusion protein specific for ox40 and pd-l1
KR20240122784A (ko) * 2021-12-17 2024-08-13 상하이 헨리우스 바이오테크, 인크. 항-ox40 항체 및 사용 방법
CN119768433A (zh) * 2022-06-28 2025-04-04 珠海烁星生物医药科技有限公司 单特异性和多特异性抗体
CN118515763B (zh) * 2024-07-23 2024-11-01 北京百普赛斯生物科技股份有限公司 Il-6的抗体、检测试剂盒及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121810A2 (en) 2005-05-06 2006-11-16 Providence Health System Trimeric ox40-immunoglobulin fusion protein and methods of use
JP2009504191A (ja) 2005-08-19 2009-02-05 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
JP2011024581A (ja) 2002-11-08 2011-02-10 Ablynx Nv 腫瘍壊死因子αを標的とする単一ドメイン抗体およびその使用
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
WO2014121099A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Agonist fusion protein for cd40 ox40 and uses thereof
US20150190506A1 (en) 2013-12-17 2015-07-09 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
CA2463879C (en) * 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
US8216996B2 (en) 2006-03-03 2012-07-10 Ono Pharmaceutical Co., Ltd. Multimer of extracellular domain of cell surface functional molecule
US20130332133A1 (en) * 2006-05-11 2013-12-12 Ramot At Tel Aviv University Ltd. Classification of Protein Sequences and Uses of Classified Proteins
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
NZ594315A (en) 2009-02-17 2013-05-31 Ucb Pharma Sa Antibody molecules having specificity for human ox40
EP3309176B1 (en) * 2009-12-14 2025-10-01 Ablynx N.V. Immunoglobulin single variable domain antibodies against ox40l, constructs and their therapeutic use
EP4012714A1 (en) * 2010-03-23 2022-06-15 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
CN103261220B (zh) 2010-08-16 2016-06-15 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
WO2013008171A1 (en) * 2011-07-11 2013-01-17 Glenmark Pharmaceuticals S.A. Antibodies that bind to ox40 and their uses
PH12021553014A1 (en) * 2012-02-27 2022-09-05 Ablynx Nv Cx3cr1-binding polypeptides
US10011660B2 (en) 2012-04-30 2018-07-03 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
JP2015524821A (ja) * 2012-08-02 2015-08-27 ジェイエヌ バイオサイエンシーズ エルエルシー システイン変異及びμ尾部を介して多量体化した抗体又は融合タンパク質
WO2014028776A1 (en) 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
AR093984A1 (es) * 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
JP2016514676A (ja) * 2013-03-15 2016-05-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 四価二重特異性抗体
SG10201708048XA (en) 2013-03-18 2017-10-30 Biocerox Prod Bv Humanized anti-cd134 (ox40) antibodies and uses thereof
US20160145355A1 (en) 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
SG10201807625PA (en) * 2014-11-17 2018-10-30 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
JP7001474B2 (ja) 2015-01-21 2022-01-19 インヒブルクス，インコーポレイティド 非免疫原性単一ドメイン抗体
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
KR20180098671A (ko) * 2016-01-11 2018-09-04 인히브릭스, 인크. 다가 및 다중특이적 ox40-결합 융합 단백질
US20200347143A1 (en) * 2016-12-19 2020-11-05 Glenmark Pharmaceuticals S.A. Novel tnfr agonists and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011024581A (ja) 2002-11-08 2011-02-10 Ablynx Nv 腫瘍壊死因子αを標的とする単一ドメイン抗体およびその使用
WO2006121810A2 (en) 2005-05-06 2006-11-16 Providence Health System Trimeric ox40-immunoglobulin fusion protein and methods of use
JP2009504191A (ja) 2005-08-19 2009-02-05 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
WO2014121099A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Agonist fusion protein for cd40 ox40 and uses thereof
US20150190506A1 (en) 2013-12-17 2015-07-09 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ｔｒｅｎｄｓ ｉｎ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ，２０１０，Ｖｏｌ．２８，ｐｐ．３５２－３６２

Also Published As

Publication number Publication date
JP2022185021A (ja) 2022-12-13
KR20180098671A (ko) 2018-09-04
MX2018008310A (es) 2019-01-28
US20170198051A1 (en) 2017-07-13
EP3402507A2 (en) 2018-11-21
US20220106397A1 (en) 2022-04-07
US20190263916A1 (en) 2019-08-29
IL260531B1 (en) 2023-01-01
WO2017123673A3 (en) 2017-08-24
MX2024004017A (es) 2024-05-08
CA3009075A1 (en) 2017-07-20
IL260531B2 (en) 2023-05-01
AU2017207318A1 (en) 2018-07-12
NZ743731A (en) 2025-06-27
AU2024200551A1 (en) 2024-02-22
AU2017207318B2 (en) 2023-12-07
US11117972B2 (en) 2021-09-14
JP2025081649A (ja) 2025-05-27
US12227584B2 (en) 2025-02-18
WO2017123673A2 (en) 2017-07-20
RU2022106508A (ru) 2022-04-05
EP3402507A4 (en) 2019-08-07
RU2018128629A3 (https=) 2020-06-16
RU2018128629A (ru) 2020-02-13
IL260531A (https=) 2018-08-30
JP2019504062A (ja) 2019-02-14
SG11201805422WA (en) 2018-07-30
CN108883153A (zh) 2018-11-23
IL298686A (en) 2023-01-01
BR112018013911A2 (pt) 2018-12-18

Similar Documents

Publication Publication Date Title
JP7328761B2 (ja) 多価多重特異性ｏｘ４０結合融合タンパク質
JP7510447B2 (ja) Ｐｄ－ｌ１－結合融合タンパク質
JP2025081307A (ja) Ｎｋ細胞結合抗体融合構築物
KR20230084507A (ko) 다중-특이적 면역 표적화 분자 및 그의 용도
EP3288974B1 (en) Type iii secretion system targeting molecules
US20250122299A1 (en) ANTI-CD20 x ANTI-CD28 COMBINATION THERAPIES
CN115175936B (zh) 用于治疗实体瘤的靶向间皮素的cd40激动性多特异性抗体构建体
RU2773052C2 (ru) Поливалентные и полиспецифические ох40-связывающие слитые белки
RU2789648C2 (ru) Мультивалентные и мультиспецифические 41bb-связывающие слитые белки
RU2779489C2 (ru) Антитела, связывающие cd3
HK1250991B (en) Type iii secretion system targeting molecules

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211223

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220531

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220928

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20221011

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20221011

C876 Explanation why request for accelerated appeal examination is justified

Free format text: JAPANESE INTERMEDIATE CODE: C876

Effective date: 20221110

C305 Report on accelerated appeal examination

Free format text: JAPANESE INTERMEDIATE CODE: C305

Effective date: 20221115

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20221122

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20221213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230309

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20230411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230602

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230804

R150 Certificate of patent or registration of utility model

Ref document number: 7328761

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350